Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including sig ...

Hutchmed expects to record a gain of $477m from the deal and plans to invest the proceeds to develop its internal pipeline. See why I rate HCM stock a Hold.

It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation ...

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...

The "Abbott Elementary" actor also shared words of encouragement she received from Cicely Tyson, Maya Angelou and Sidney ...

Cancer has long been one of the most feared diseases in the world. Now, a groundbreaking development in vaccine technology ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load.

The Global Digital Medicine market is experiencing significant growth driven by several key market drivers. Increased smartphone penetration ...

A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more ...